Trial
NCT04348643
Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Chongqing Precision Biotech Co., Ltd
Collaborators
—
Condition
Solid Tumor
Intervention
CEA CAR-T cells
Why stopped
The sponsor requested to terminate the study.
Provenance
Dataset: 2026-07-10 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-10